Serum Steroids in Relation to Prostate Cancer Risk in a Case-Control Study (Greece)
β Scribed by Lisa B. Signorello, Anastasia Tzonou, Christos S. Mantzoros, Loren Lipworth, Pagona Lagiou, Chung-cheng Hsieh, Meir Stampfer and Dimitrios Trichopoulos
- Book ID
- 125282167
- Publisher
- Springer Netherlands
- Year
- 1997
- Tongue
- English
- Weight
- 888 KB
- Volume
- 8
- Category
- Article
- ISSN
- 0957-5243
- DOI
- 10.2307/3552743
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
A case-control study of prostate cancer (PC) was undertaken in Athens, Greece. Cases were 320 patients with histologically confirmed incident disease, whereas controls were 246 patients without history or symptomatology of benign prostatic hyperplasia, treated in the same hospitals as the cases for
## Objective Finasteride reduces prostate cancer risk by blocking the conversion of testosterone to dihydrotestosterone. However, whether finasteride affects estrogens levels or change in estrogens affects prostate cancer risk is unknown. ## Methods These questions were investigated in a caseβcon
The nutritional aetiology of prostate cancer was evaluated in Athens, Greece, through a case-control study that included 320 patients with histologically confirmed incident prostate cancer and 246 controls without history or symptomatology of benign prostatic hyperplasia or prostate cancer, treated